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Background: The transforming growth factor (TGF)- family of cytokines exerts pleiotropic actions on vascular smooth
muscle cell phenotype, proliferation, and extracellular matrix synthesis. This in vivo study assessed the use of TGF-3 in
attenuating the development of postanastomotic smooth muscle cell proliferation.
Methods: Under general anesthesia, 10 adult goats underwent transection and reanastomosis of both common carotid
arteries. After reanastomosis, one artery was infiltrated with 50 ng of TGF-3 in 100 L of pH buffer around the
anastomosis, and the other side was infiltrated with buffer only. After surgery, each animal received 150 mg of aspirin
daily. The arteries were explanted after 3 months for histologic examination.
Results: Vessel wall thickness surrounding the anastomosis was reduced by 30% after TGF-3 treatment compared with
placebo (P  .003), with a 20% (P  .002) reduction in cellular content. Although total collagen content was not
significantly different between TGF-3 and placebo, collagen type VIII content was reduced around the TGF-3
anastomoses (P  .011). A reduction in the total elastin content (P  .003) and number of elastic fiber lamellae (P 
.042) was found surrounding TGF-3–treated anastomoses, but not placebo-treated anastomosis. A 29% increase in vasa
vasorum (P  .044) was present around TGF-3–treated anastomoses. No differences in inflammatory cell infiltration
were seen between sides.
Conclusions:Direct subadventitial infiltration of TGF-3 immediately after creation of an arterial anastomosis attenuates
cell proliferation, with a reduction in elastin and collagen type VIII content and vessel wall thickness. ( J Vasc Surg 2006;
43:142-9.)
Clinical Relevance: Peripheral arterial bypass graft failure, particularly in the context of critical limb ischemia, has a
considerable effect in terms of patient morbidity andmortality, human resources, and financial burden. The predominant
etiology of arterial bypass graft failure is encroachment of the vessel lumen by myointimal hyperplasia (MIH). This
typically becomes clinically significant 12 to 24 months after surgery. A principal factor in the pathogenesis of MIH
development is the proliferation and migration of smooth muscle cells (SMCs) from the tunica media toward the luminal
surface. These SMCs dedifferentiate away from the quiescent contractile phenotype ordinarily found in mature vessels
into a more immature, synthetic phenotype that is characterized by rapid proliferation and extracellular matrix
deposition. The transforming growth factor (TGF)- family of proteins are multifunctional growth factors that exert a
profound influence over the proliferation, extracellular matrix synthesis, and contractile function of numerous cell types.
This study demonstrates in an animal model that a single dose of subadventitial TGF-3 to an artery immediately after
wounding attenuates cell proliferation and vessel wall thickness, with a reduction in elastin deposition and collagen type
VIII, an important component of the neointima and a promoter of SMC migration and invasion. Thus, TGF-3 would
seem to have potential as prophylaxis against MIH-related bypass graft failure.Peripheral arterial bypass graft failure, particularly in
the context of critical limb ischemia, has a considerable
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142effect in terms of patient morbidity and mortality, human
resources, and financial burden. Whereas satisfactory pa-
tency rates may be achieved by using both autologous vein
and synthetic conduits in high-flow large-diameter vessels
(6 mm),1 the long-term success of infracrural bypass is
less encouraging. Indeed, 4-year patency rates of only 49%
and 12% for vein and prosthetic grafts, respectively, have
been described,2 and this creates a clinical dilemma because
up to 30% of patients requiring peripheral artery bypass do
not possess an adequate vein for harvest.3
The predominant etiology of arterial bypass graft fail-
ure is encroachment of the vessel lumen by myointimal
hyperplasia (MIH), which typically becomes clinically sig-
nificant 12 to 24 months after surgery.4 MIH lesions
appear pale, firm, and homogenous and consist predomi-
nantly of extracellular matrix (ECM) molecules, including
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proteoglycans.5 A principal factor in the pathogenesis of
MIH development is the proliferation and migration of
smooth muscle cells (SMCs) from the tunica media toward
the luminal surface.6,7 The invasion of SMCs into the
lumen represents an adaptive response by these cells to the
altered hemodynamic milieu, compliance mismatch, and
direct exposure to luminal shear forces after desquamation
of endothelia after arteriotomy.8-10 These SMCs dediffer-
entiate away from the quiescent contractile phenotype or-
dinarily found in mature vessels into a more immature,
synthetic phenotype that is characterized by rapid prolifer-
ation and ECM deposition.9-12
The transforming growth factor (TGF)- family of
proteins are multifunctional growth factors that exert a
profound influence over the proliferation, ECM synthesis,
and contractile function of numerous cell types. In partic-
ular, the TGF-1 isoform, produced by SMCs, endothelia,
and fibroblasts, plays a key role during vascular develop-
ment and disease.13-18 Furthermore, the expression of
TGF-1 by these cells within the developing MIH lesion is
increased in concert with SMC proliferation and migra-
tion.12,19-22 Chamberlain et al,19 in a porcine coronary
angioplasty model of arterial injury, demonstrated that
local levels of active TGF-1 increase early after vessel
injury, peak after 7 days, and return to normal after 28 days.
Concurrently, more factors associated with TGF-1 activa-
tion were also observed.19,23
The arterial response to injury bears much homology to
that of skin after dermal incision.24 The release of TGF-1
by platelets, macrophages, and fibroblasts locally to the
region of injury in adults is analogous to that by vascular
SMCs after arterial wounding. It is interesting to note that
this release is uncharacteristic of fetal incisional wounds, in
which a reduced ratio between TGF-1 and TGF-3 is
associated with scar-free healing and reduced inflamma-
tion.17,25 After such observations, local infiltration of re-
combinant TGF-3 to incisional skin wounds has been
demonstrated to significantly reduce wound volume and to
decrease scarring.26 It is also interesting to note that the
scar-preventing and -reducing effects in the skin can be
achieved after an acute application of TGF-3 at the time
of, or slightly after, injury.26 TGF-3 is currently undergo-
ing human clinical trials as a locally administered drug to
prevent and reduce scarring.
Fibroblasts and SMCs, both derived from mesenchy-
mal stem cells, share many characteristics, including ECM
synthesis. Indeed, many consider a continuum to exist
between fibroblasts, myofibroblasts, and SMCs.27-29 From
these assertions, it was hypothesized that TGF-3, locally
delivered to a vascular anastomosis at operation, would
attenuate the development of MIH by limiting SMC pro-
liferation and ECMdeposition. The aim of this study was to
test this hypothesis.
METHODS
Animal model and surgical procedures. All proce-
dures were performed with the authorization of the HomeOffice and complied with the Animals (Scientific Proce-
dures) Act of 1986. To meet Home Office requirements,
power calculations were performed to calculate the mini-
mum number of animals required to provide data with 80%
statistical power. Thus, 10 female adult goats (65-95 kg)
were used for this study. The animals were allowed to
acclimatize to their new environment for at least 1 week
before undergoing study procedures. The animals were fed
on normal laboratory chow without lipid supplementation
for the duration of the experiment.
All goats were premedicated with 150 mg of aspirin for
48 hours before surgery and given nil by mouth overnight.
Induction of anesthesia was achieved by using inhaled 2%
isoflurane, nitrous oxide (2 L/min), and oxygen (2 L/min)
delivery through a tight-fitting conical mask. No paralyzing
agents were used, and the anesthesia used allowed sponta-
neous respiration. After intravenous injection of midazo-
lam, carefully titrated to abolish laryngeal spasm, a size 9
endotracheal tube was sited down to the mid trachea and
secured. Heart rate and arterial blood pressure monitoring
were commenced by connection of an intra-arterial cannula
to a disposable pressure transducer (Edwards Lifescience,
Irvine, Calif) and displayed on a monitor, Datex-Ohmeda
(Hatfield, Herts, UK). Rectal temperature measurements
were performed during surgery, and oxygen saturation was
constantly monitored.
The ventral surface of the neck was shaved and prepared
with aqueous iodine for asepsis, and the surrounding area
was covered with sterile drapes. After intravenous injection
of 1 g of flucloxacillin for antistaphylococcal antibiotic
cover, a midline pretracheal incision was made from the
level of the cricoid cartilage to the base of the neck. After
division of platysma, a substernomastoid plane was devel-
oped on either side to reveal both common carotid arteries.
After exposure of at least 5 cm of artery, 2000 U of heparin
(Leo, Princes Risborough, UK) was administered intrave-
nously, with 2 minutes allowed for systemic distribution.
Each artery was transected transversely between clamps and
then anastomosed by using a continuous Prolene 6.0 su-
ture (Ethicon Limited, Edinburgh, UK). The adventitia of
one vessel was then infiltrated through a 24-gauge needle
on either side of the anastomosis with 50 ng of TGF-3
constituted in 100 L of pH 7.4 buffer containing phos-
phate-buffered saline and mannitol (Fig 1). The other
vessel was infiltrated with 100 L of buffer only as a
control. After clamp release and securing of hemostasis, the
wound was closed by using 2.0 Vicryl (Ethicon Limited)
for the platysma and 4.0 Vicryl for subcuticular sutures.
The animals were allowed to recover and given postopera-
tive analgesia as required. Thereafter, 150mg of aspirin was
given daily to each animal as antiplatelet therapy. Three
months after surgery, each animal was humanely killed by
using intravenous sodium phenobarbital, after which each
common carotid artery was explanted.
Tissue preparation. Segments of common carotid ar-
tery incorporating 2 cm on either side of the suture line
were explanted, with the ends of the vessels left open. After
irrigation with normal saline, the explanted arteries under-
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hyde solution, maintained at 4°C overnight. The rate of
penetration of the explanted specimens by paraformalde-
hyde with immersion fixation was found to be sufficient
according to the calculus by Medawar in cases.30 Within 24
hours, the vessels were opened longitudinally and dissected
to form four longitudinal strips, which were embedded in
paraffin wax. In this manner, 5-m cross sections from four
quadrants of each vessel were cut for histologic analysis.
Histologic staining. Sections were stained with Har-
ris hematoxylin and eosin (H&E) and Miller elastin stain
(all solutions from Raymond Lamb, East Sussex, UK;
LAMB/014-D, LAMB/007-D, and LAMB/006-D). Im-
munohistochemical staining for collagen type VIII was
performed by using a three-stage immunoperoxidase-re-
vealing system. Antigen unmasking was performed by in-
cubation with hyaluronidase at 37°C for 30 minutes, and
endogenous peroxidases were blocked with 0.9% hydrogen
peroxide in methanol. Monoclonal mouse anti-human pri-
mary antibody to collagen type VIII for an hour (1:200;
Fig 1. Hematoxylin and eosin–stained sections taken from the
same animal. A, Placebo-treated anastomoses. B, After transform-
ing growth factor (TGF)-3 treatment. *Suture line. Solid arrow
represents the combined thickness of the media and intima at the
anastomosis; dashed arrow represents the normal surrounding
vessel. There was an overall reduction in anastomosis thickness
after TGF-3 compared with placebo, as evidenced by the Intima
 Media ratio between the anastomosis and surrounding artery
(original magnification, 4).Seikagaku Corporation, Tokyo, Japan) was applied, fol-lowed by donkey anti-mouse secondary antibody for an-
other hour. After incubation with an avidin-biotin-peroxi-
dase complex (Vector Laboratories, Peterborough, UK),
sections were developed with freshly prepared NovoRed
(Vector Laboratories). The sections were then counter-
stained with Harris hematoxylin and mounted in XAM
neutral medium (BDH, Poole, UK). Immunopositivity was
seen as a red stain, and nuclei were stained blue. Control
slides were prepared as described previously, but without
application of primary antibody.
Analysis. All analyses were performed in a blinded
fashion by the same investigator. Morphologic analysis of
slides was performed by viewing H&E sections. The num-
ber of vasa vasorum was counted in an 10 magnification
field centered on the suture line. Inflammatory cell infiltra-
tion, identified by cell appearance from an H&E-stained
section, was qualitatively assessed. The maximal combined
thickness of the intima/neointima plus media at the anas-
tomosis was measured and expressed as a ratio to surround-
ing normal artery, hereafter termed the IM ratio. For
quantitative evaluation of elastin and collagen type VIII
content, investigations were performed with a Leica LB2
microscope, and image analysis was performed with Leica
QWin software (Leica Microsystems, Milton Keynes, UK).
Image analysis was additionally performed to count the
number of nuclei per40 field of view of the luminal aspect
of the vessel wall, centered over the suture line. Total
collagen content was analyzed by measuring the lumines-
cence of circular polarized light. The total area of positive
pixilation in an 4 magnification field centered on the
anastomosis was measured.
Statistical analysis. All analyses were performed in
triplicate, and numerical data were pooled. Results are
expressed as mean  SD. Statistical differences between
groups were tested by two-tailed Student t tests. P  .05
was considered significant.
RESULTS
Pooled data (mean SD) from all subjects are summa-
rized in the Table. Figure 1 demonstrates representative
H&E-stained histologic sections from the same animal,
illustrating the difference in SMC distribution between
placebo-treated and TGF-3–treated anastomoses. All but
two animals showed reduced IM thickness after infiltra-
tion with TGF-3, and, overall, there was a 30% reduction
in the TGF-3–treated vessels compared with placebo (P
.003). Automated counts of hematoxylin-stained nuclei
revealed a mean of 2934 (SD, 490) cells per 40 field of
view in placebo-treated vessels compared with 2356 (SD,
527) after TGF-3 treatment, constituting a 19.7% reduc-
tion in cellular content associated with TGF-3 treatment
(P  .002). There was no difference in the degree of
inflammatory cell infiltration between TGF-3–treated and
placebo-treated arteries. This comprised mononuclear cell
aggregation around the suture lines, consistent with a
foreign body reaction. There was a twofold increase in the
number of vasa vasorum in placebo-treated groups in com-
parison to normal unoperated arteries, and there was a
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anastomoses.
Representative images demonstrating elastin deposi-
tion are shown in Fig 2. Overall, there was a 24% reduction
in total elastin deposition surrounding TGF-3–treated
anastomoses compared with placebo (P  .031). In addi-
tion, TGF-3 treatment was associated with a reduction in
elastic lamellae units compared with the placebo-treated
artery (P  .003). The numbers of elastic lamellae in the
TGF-3–treated vessels were similar to those in unoperated
vessels. Representative micrographs for total collagen con-
tent are shown in Fig 3. There was a twofold increase in
collagen content surrounding both TGF-3–treated and
placebo-treated anastomoses compared with surrounding
unoperated vessels, although there was no significant dif-
ference between sides at the site of arteriotomy (P .988).
Representative micrographs for collagen type VIII deposi-
tion are shown in Fig 4. There was an overall 32% reduction
Fig 2. Monochrome image of Miller elastin–stained sections,
both from the same animal, demonstrating reduced total elastin
content after TGF-3 treatment (A) with decreased numbers of
lamellae (arrowhead) compared with placebo (B). *Suture line
(original magnification, 4). IEL, internal elastic lamella; EEL,
external elastic lamella.of collagen type VIII content after TGF-3 treatment incomparison to placebo (P  .011). The distribution of
collagen type VIII extended from the neointima to the
adventitia.
DISCUSSION
For these studies, the adult caprine common carotid
artery model was used, because it simulates the hemody-
namic forces encountered in human superficial femoral and
popliteal arteries31 and has been validated in a previous
investigation.32 An added advantage is that, because two
common carotid arteries are available, each animal provides
its own control vessel, thus eliminating confounding inter-
individual variation. Because the region of arterial injury in
this model was slim, specimens were cut longitudinally to
yield adequate numbers of sections for analysis.
The dose of TGF-3 administered in this study, 50 ng,
is the optimal dose that has been found to encourage
scar-free healing in experimental skin models.25,26 TGF-3
was constituted into a volume of 100 L because this was
found to permit delivery of the protein around the entire
circumference of the anastomosis without causing excessive
trauma or generating dissection. Because TGF-3 infiltra-
tion aimed to attenuate SMC proliferation and migration
from the media to limit MIH development, the intima plus
media thickness was assessed. TGF-3 reduced the cellular
content of the region surrounding the arteriotomy by 20%
and the IM ratio by almost a third. The increases in type
VIII collagen and elastin content were also attenuated by
treatment with TGF-3. It is noteworthy that, in vitro,
collagen type VIII and elastin are upregulated by exoge-
nous TGF-1 supplementation and adenoviral transfec-
tion.33 Although elastin deposition in postnatal vessels is
minimal,34 increased elastin content has been observed
after arterial injury.35 The mechanisms underlying the in-
crease in elastic fibers and the number of lamellae require
further elucidation, although the attenuation of both orga-
nized and unorganized elastic fibers by TGF-3 suggests
that these may be TGF-1–mediated events. Collagen type
VIII is a short-chain collagen normally found in the suben-
dothelial layer and in medial elastic lamellae, and it is
markedly upregulated after arterial injury.36-41 Further-
more, collagen type VIII has been found to play a crucial
role in SMC invasion after vascular injury by supporting
attachment and migration of SMCs and by acting as a
potent chemotactic factor.37,42 Thus, TGF-3 suppression
of collagen type VIII deposition may limit SMC invasion in
MIH, in addition to reducing ECM volume. Total collagen
content, predominantly type I collagen, was unchanged as
a consequence of TGF-3 application. In skin models,
application of TGF-3 produces an early reduction of
collagen, but at later time points after wounding, there is
no significant difference.25,26 However, in skin wounds,
TGF-3 markedly alters the structure and organization of
the dermal ECM, and this results in an arrangement that
more closely resembles that of the normal unwounded
skin.25,26 The effects on arterial repair seem very similar:
the structure and organization of the anastomosis site more
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than those of the placebo control.
TGF-3 has been found to be proangiogenic in skin
Fig 3. Total collagen content visualized by refraction o
within the vessel wall was seen after surgery with placebo i
no difference was observed between placebo (B) and T
magnification, 4).models.17,25 Accordingly, the number of vasa vasorum wasinvestigated. There was a substantial increase in small ves-
sels in TGF-3–treated vessels relative to placebo, although
both containedmore vessels than an unoperated artery. It is
rized light. A two-fold increase in total collagen content
ation, in comparison to unoperated artery (A). However,
3 (C) treatment. Arrow highlights suture line (originalf pola
nfiltr
GF-familiar surgical dogma that successful healing and resis-
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Thus, a secondary benefit associated with TGF-3 admin-
istration is an improvement in blood supply to the adven-
titia during the early healing phase.
TGF-1 signaling has been investigated by others as a
potential means of inhibiting luminal loss after balloon
angioplasty,43-45 although not after arteriotomy and for-
mation of an anastomosis. Smith et al,45 using a recombi-
nant soluble TGF- receptor II to inhibit TGF- signaling
in a rat carotid model, reported a 60% reduction of luminal
Fig 4. Collagen type VIII staining is highlighted by the arrow.
Reduced type VIII collagen content was seen after treatment with
TGF-3 (A) compared with placebo (B). A control slide is shown
in (C) (original magnification, 4).loss by preventing vessel shrinkage through negative re-modeling after injury. Although there was a reduction of
neointimal cellularity, the actual size of the neointima was
not significantly altered in this study. Kingston et al43
delivered an adenoviral vector–expressing secreted form of
TGF- receptor II into porcine coronary arteries after
angioplasty. Again, there was a decrease in luminal loss due
to inhibition of restrictive remodeling, with an increase in
collagen synthesis from the adventitia not seen in nonex-
pressing adenoviral controls. In a second study by the same
group,44 local delivery of a TGF-3– expressing viral vector
inhibited constrictive remodeling and reduced luminal loss,
although again there was an increase in adventitial collagen.
It was suggested that, at least in porcine coronary vessels,
this neoadventitial ring acts as a scaffold to resist constric-
tion. In this study, TGF-3 infiltration, in comparison to
placebo, was associated with reduced cellularity, but not
total collagen content. It may be inferred that the total
amount of collagen synthesis per cell during the 3-month
period following arteriotomy was therefore greater after
TGF-3 treatment. Our study also differs in the type of
injury. Our study was a deliberate inquiry into the effects of
TGF-3 on an anastomosis, rather than arterial injury after
angioplasty, as investigated in the aforementioned studies.
It is noteworthy that the diffuse transmural injury from
balloon overexpansion during angioplasty is potentially
more traumatic than a clean transection with localized
endothelium desquamation and ischemia from the suture
line.
CONCLUSION
This study demonstrates that a single dose of subadven-
titial TGF-3 immediately after arterial wounding results in
reduced cellular content and deposition of key vascular
ECM molecules around the anastomosis. Significantly,
deposition of collagen type VIII, an important component
of the neointima and a promoter of SMC migration and
invasion, is diminished. TGF-3 has a low toxicity profile
and a high first-pass metabolism. Moreover, the mode of
delivery minimizes systemic effects and is easily performed
by the surgeon during surgery. It is appreciated that arte-
rioarterial anastomoses produce little compliance mismatch
and clinically significant MIH.
Nevertheless, TGF-3 seems to have potential as a
Overall data
Variable Placebo TGF-3
Intima Media ratio 2.78 (0.486) 1.96 (0.61)
Nuclei per 40 field 2934 (490) 2356 (527)
No. Vasa vasorum per 10 field 39.7 (12) 55.8 (10)
Elastin (pixilation per 4 field) 46.2 (14.3) 37.7 (15.9)
Collagen type VIII (pixilation
per 4 field)
99.3 (21.6) 69.9 (16.5)
No. Of elastic laminae
surrounding anastomosis
6.85 (1.61) 5.04 (1.31)
Collagen content (pixilation per
4 field)
778 (230) 733 (240)
TGF, Transforming growth factor.prophylaxis against MIH-related bypass graft failure. Fur-
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loss is affected in the long term, particularly in the setting of
small-diameter bypass graft anastomoses, and to establish
optimal dosage and delivery.(Table)
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